Asian Biomedicine最新文献

筛选
英文 中文
The role and advantages of intraductal ultrasound for the management of gallstones. 导管内超声在胆结石治疗中的作用和优势。
IF 1.4 4区 医学
Asian Biomedicine Pub Date : 2026-04-30 eCollection Date: 2026-02-01 DOI: 10.2478/abm-2026-0001
{"title":"The role and advantages of intraductal ultrasound for the management of gallstones.","authors":"","doi":"10.2478/abm-2026-0001","DOIUrl":"10.2478/abm-2026-0001","url":null,"abstract":"","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 1","pages":"1-2"},"PeriodicalIF":1.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147810125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of GnRH-a in combination with dienogest therapy in endometriosis and its effects in recurrence and pregnancy status. GnRH-a联合dienogest治疗子宫内膜异位症的疗效及其对复发和妊娠状态的影响。
IF 1.4 4区 医学
Asian Biomedicine Pub Date : 2026-04-30 eCollection Date: 2026-02-01 DOI: 10.2478/abm-2026-0005
Ke Zhou, Rong Zhu, Yue Jin
{"title":"Efficacy of GnRH-a in combination with dienogest therapy in endometriosis and its effects in recurrence and pregnancy status.","authors":"Ke Zhou, Rong Zhu, Yue Jin","doi":"10.2478/abm-2026-0005","DOIUrl":"10.2478/abm-2026-0005","url":null,"abstract":"<p><strong>Background: </strong>Endometriosis (EMT) is a common gynecologic and hormone-dependent disease that seriously affects patients' quality of life and currently faces certain challenges in clinical treatment.</p><p><strong>Objective: </strong>To observe the clinical efficacy of gonadotropin-releasing hormone agonists (GnRH-a) in combination with Dienogest treatment in EMT and its effects on recurrence and pregnancy.</p><p><strong>Methods: </strong>In a retrospective study, 254 patients with EMT from The First Affiliated Hospital, College of Medicine, Zhejiang University were selected between October 2020 and December 2021, and were divided into DT group (Dienogest treatment group) and GD group (GnRH-a combined with dienogest treatment group) according to the treatment modality, both groups were treated with Dienogest, and the GD group was additionally treated with GnRH-a. The primary assessment of both groups was clinical efficacy, recurrence rate and pregnancy (cumulative pregnancy rate, live birth rate, miscarriage rate, multiple pregnancy rate, and ectopic pregnancy rate). Secondary outcomes included the antibody indicator positive rate (anti-endometrial antibodies [AEmAb], anti-sperm antibodies [AsAb], and anti-zona pellucida antibodies [AZpAb]), sex hormone levels (luteinizing hormone [LH], follicle-stimulating hormone [FSH], and estradiol [E2]), serum inflammatory indicator levels (Interleukin-6 [IL-6], C-reactive protein [CRP], tumor necrosis factor-α [TNF-α]), visual analog scale (VAS) scores, and adverse reactions.</p><p><strong>Results: </strong>After treatment, all indicators improved in both groups (<i>P</i> < 0.05). The clinical efficacy, cumulative pregnancy rate, and live birth rate of patients in the GD group were markedly higher than those in the DT group (<i>P</i> < 0.05). The recurrence rate, positive rate of antibody indicator, sex hormone level, serum inflammation indicator, VAS score, and incidence of adverse reactions of patients in the GD group were remarkably below the DT group (<i>P</i> < 0.05). No marked discrepancies were found in the rates of miscarriage, multiple pregnancy, and ectopic pregnancy in both groups (<i>P</i> > 0.05).</p><p><strong>Conclusion: </strong>The efficacy of GnRH-a combined with Dienogest in the treatment of EMT is remarkable, which can effectively reduce the inflammatory response, sex hormone levels, and recurrence rate, and markedly improve pregnancy, which is worth promoting its use in the clinic.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 1","pages":"41-52"},"PeriodicalIF":1.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147810026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial functional ingredients used in hand hygiene products: a cross-sectional survey on regional e-commerce platforms in Wuhan area of China. 手卫生用品中抗菌功能成分使用情况:武汉地区区域电商平台横断面调查
IF 1.4 4区 医学
Asian Biomedicine Pub Date : 2025-12-31 eCollection Date: 2025-12-01 DOI: 10.2478/abm-2025-0037
Xintong Chen, Jun Wang
{"title":"Antimicrobial functional ingredients used in hand hygiene products: a cross-sectional survey on regional e-commerce platforms in Wuhan area of China.","authors":"Xintong Chen, Jun Wang","doi":"10.2478/abm-2025-0037","DOIUrl":"10.2478/abm-2025-0037","url":null,"abstract":"<p><strong>Background: </strong>Hand hygiene products containing antimicrobial functional ingredients have become daily products for many people during the post-pandemic period. However, their current market scenarios have not been well explored.</p><p><strong>Objective: </strong>To provide an overview of antimicrobial functional ingredients in hand sanitizer products marketed to the public in Wuhan, China.</p><p><strong>Methods: </strong>This cross-sectional product survey was conducted in September 2023. Information about existing hand hygiene products available online for household use was obtained from 2 major local e-commerce platforms in the Wuhan area of China: Tmall Supermarket and Jingdong Supermarket.</p><p><strong>Results: </strong>A total of 674 hand sanitizer products were included in the survey, which were evenly divided into alcohol-based and alcohol-free sanitizers. More than 22 non-alcoholic compounds were used in alcohol-free hand sanitizer products, among which the top 5 major ingredients were benzalkonium chloride (BAC), iodine-based compounds, chloroxylenol (CX), hypochlorous acid, and polyhexamethylene biguanide. A majority (83.2%) of hand sanitizer products available on e-commerce platforms were single-ingredient formulations, with the remaining 16.8% containing sanitizers in combination. Triclosan (TCS)/triclocarban (TCC)-containing products accounted for 4.2% of all the included products and 8.3% of alcohol-free products; their recognized alternatives BAC/benzethonium chloride/CX had replaced the role of TCS/TCC in hand sanitization, especially in liquid hand rubs, antiseptic hand wipes, and liquid soaps. A total of 13 natural antimicrobial ingredients were identified in 2.1% of all the products.</p><p><strong>Conclusion: </strong>There was a booming and diversified hand sanitizer market in Wuhan, China during the post-pandemic era. A market shift from alcohol-based to alcohol-free hand sanitizers has emerged.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 6","pages":"383-393"},"PeriodicalIF":1.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12919381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2024 Thai guidelines on the treatment of hypertension. 2024年泰国高血压治疗指南。
IF 1.4 4区 医学
Asian Biomedicine Pub Date : 2025-12-31 eCollection Date: 2025-12-01 DOI: 10.2478/abm-2025-0034
Sirisawat Kunanon, Praew Kotruchin, Pairoj Chattranukulchai, Chavalit Chotruangnapa, Weranuj Roubsanthisuk, Prin Vathesatogkit, Tada Kunavisarut, Songkwan Silaruks, Sirakarn Tejavanija, Tuangsit Wataganara, Piengbulan Yapan, Nijasri Suwanwela, Pongamorn Bunnag, Buncha Satirapoj, Surapun Sitthisook, Rapeephon Kunjara Na Ayudhya, Apichard Sukonthasarn
{"title":"2024 Thai guidelines on the treatment of hypertension.","authors":"Sirisawat Kunanon, Praew Kotruchin, Pairoj Chattranukulchai, Chavalit Chotruangnapa, Weranuj Roubsanthisuk, Prin Vathesatogkit, Tada Kunavisarut, Songkwan Silaruks, Sirakarn Tejavanija, Tuangsit Wataganara, Piengbulan Yapan, Nijasri Suwanwela, Pongamorn Bunnag, Buncha Satirapoj, Surapun Sitthisook, Rapeephon Kunjara Na Ayudhya, Apichard Sukonthasarn","doi":"10.2478/abm-2025-0034","DOIUrl":"10.2478/abm-2025-0034","url":null,"abstract":"<p><p>The committee of the 2024 Thai Guidelines on the Treatment of Hypertension has reviewed new developments in the body of knowledge, combined with expertise in real-life clinical practice and evidence collected from clinical studies worldwide. The Guidelines consist of newly highlighted key topics to be up to date and suitable for the country's context. We still maintained the current office blood pressure (BP) cut-point of 140/90 mmHg for hypertension diagnosis. The new BP category, \"BP at risk,\" i.e., BP of 130-139/80-89 mmHg, was introduced. The out-of-office BP measurements, including home BP monitoring (HBPM) or ambulatory blood pressure monitoring (ABPM), are also advocated to confirm the diagnosis of hypertension. Target BP levels depend on the age of the patients i.e., 120-130/70-79 mmHg for patients age 18-65 years, 130-139/70-79 mmHg for patients over 65 years of age. There are 5 main groups of antihypertensive medication, that is, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, betablockers, calcium-channel blockers, and diuretics (thiazides and thiazide-like diuretics such as chlorthalidone and indapamide). Two types of medications should be started for most patients, except for frail elderly patients, patients with relatively low initial BP (140-149/90-99 mmHg), and low-risk patients; only 1 type of starting medication should be selected. Medication that is a combination of 2 types in 1 pill should be selected. Patient empowerment can be useful in sharing decisions in goal setting, provision of feedback channels, self-monitoring, education, and motivation, which the use of telemedicine and mobile health technologies can assist.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 6","pages":"316-357"},"PeriodicalIF":1.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12919385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticancer potential of fused heterocycles: structural insights and mechanistic advances. 融合杂环化合物的抗癌潜力:结构见解和机制进展。
IF 1.4 4区 医学
Asian Biomedicine Pub Date : 2025-12-31 eCollection Date: 2025-12-01 DOI: 10.2478/abm-2025-0035
Aaysha Pandey, Shubham Sharma, Kamal Kishore, Swati Rani, Man Vir Singh, Gangotri Pemawat
{"title":"Anticancer potential of fused heterocycles: structural insights and mechanistic advances.","authors":"Aaysha Pandey, Shubham Sharma, Kamal Kishore, Swati Rani, Man Vir Singh, Gangotri Pemawat","doi":"10.2478/abm-2025-0035","DOIUrl":"10.2478/abm-2025-0035","url":null,"abstract":"<p><p>β-lactam derivatives, carbazoles, isatin derivatives, pyrrolo-benzodiazepines (PBDs), and pyrido[2,3-d]pyrimidines have demonstrated potential as anticancer agents among organic compounds. They exhibit substantial anticancer efficacy across several cancer cell lines, such as HL-60, THP-1, U-937, HeLa, PANC1, MDA-MB-231, and A549 cell lines. These compounds display a significant anticancer profile via diverse biological pathways such as DNA interaction, kinase inhibition, microtubule disruption, and enzyme inhibition. Their low IC50 values across various cell lines suggest their viability as strong candidates for targeted and multi-mechanistic cancer therapy, warranting further in vivo and clinical exploration. This review thoroughly summarized the anticancer efficacy of <i>β</i>-lactam derivatives, carbazoles, isatins, PBDs, and pyrido[2,3-d]pyrimidine derivatives.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 6","pages":"358-374"},"PeriodicalIF":1.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12919380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recombinant phospholipase A2 inhibitor of Sinonatrix annularis (ringed water snake) attenuates hemorrhagic action of the venom from Daboia siamensis (Siamese Russell's viper). 重组环状水蛇(Sinonatrix annularis)的磷脂酶A2抑制剂减弱了暹罗毒蛇(Daboia siamensis)毒液的出血作用。
IF 1.4 4区 医学
Asian Biomedicine Pub Date : 2025-12-31 eCollection Date: 2025-12-01 DOI: 10.2478/abm-2025-0038
Wichit Thaveekarn, Jureeporn Noiphrom, Asada Leelahavanichkul, Orawan Khow
{"title":"Recombinant phospholipase A<sub>2</sub> inhibitor of <i>Sinonatrix annularis</i> (ringed water snake) attenuates hemorrhagic action of the venom from <i>Daboia siamensis</i> (Siamese Russell's viper).","authors":"Wichit Thaveekarn, Jureeporn Noiphrom, Asada Leelahavanichkul, Orawan Khow","doi":"10.2478/abm-2025-0038","DOIUrl":"10.2478/abm-2025-0038","url":null,"abstract":"<p><strong>Background: </strong>Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) is a common enzyme in snake venoms from many species that hydrolyzes phospholipids in cell membranes, causing local and systemic adverse effects. Interestingly, PLA<sub>2</sub> inhibitors in the snake blood are a natural neutralization against PLA<sub>2</sub> that is leaked into the circulation. Hence, synthesizing liver PLA<sub>2</sub> inhibitors might be a novel and effective anti-venom strategy.</p><p><strong>Objective: </strong>To test if PLA<sub>2</sub> inhibitor gamma form (PLIϒ) reduces the hemorrhagic effect of crude <i>Daboia siamensis (D. siamensis</i>) (a venomous viper with high PLA<sub>2</sub> abundance in the venom).</p><p><strong>Methods: </strong>PLIϒ was synthesized and purified from the data of <i>Sinonatrix annularis</i>. Then, PLA<sub>2</sub> activity in the snake venoms was screened and tested against PLA<sub>2</sub> activity from crude <i>D. siamensis</i> venom. The hemorrhage effect of crude D. <i>siamensis</i> was measured with the minimum hemorrhagic activity dose in mice with and without PLIϒ.</p><p><strong>Results: </strong><i>D. siamensis</i> had the highest PLA<sub>2</sub> activity among the 5 selected venomous snakes. The PLIϒ reduced the PLA<sub>2</sub> activity of crude <i>D. siamensis</i> by up to 34.8% (<i>in vitro</i>) and decreased hemorrhagic spots in mice by up to 30.2% on the inner surface of mouse skins compared with controls.</p><p><strong>Conclusion: </strong>PLIϒ reduced PLA<sub>2</sub> activity and was effective in mitigating the hemorrhagic effect of crude <i>D. siamensis</i>.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 6","pages":"394-401"},"PeriodicalIF":1.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12919382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Basic research on antitoxin profiles: a key link to the management of snakebites. 抗毒素谱的基础研究:蛇咬伤管理的关键环节。
IF 1.4 4区 医学
Asian Biomedicine Pub Date : 2025-12-31 eCollection Date: 2025-12-01 DOI: 10.2478/abm-2025-0033
{"title":"Basic research on antitoxin profiles: a key link to the management of snakebites.","authors":"","doi":"10.2478/abm-2025-0033","DOIUrl":"10.2478/abm-2025-0033","url":null,"abstract":"","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 6","pages":"314-315"},"PeriodicalIF":1.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12919379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A beginner's guide to the clinical approach and key concepts of glomerular disease: a mini review. 肾小球疾病的临床方法和关键概念的初学者指南:一个小回顾。
IF 1.4 4区 医学
Asian Biomedicine Pub Date : 2025-12-31 eCollection Date: 2025-12-01 DOI: 10.2478/abm-2025-0036
Suwasin Udomkarnjananun, Talerngsak Kanjanabuch, Dennis A Hesselink
{"title":"A beginner's guide to the clinical approach and key concepts of glomerular disease: a mini review.","authors":"Suwasin Udomkarnjananun, Talerngsak Kanjanabuch, Dennis A Hesselink","doi":"10.2478/abm-2025-0036","DOIUrl":"10.2478/abm-2025-0036","url":null,"abstract":"<p><p>Glomerular disease is a common issue in nephrology, where prompt diagnosis and appropriate treatment are crucial to halting disease progression and preventing the development of chronic kidney disease or end-stage kidney disease. The initial approach and differential diagnosis remain essential clinical skills for ensuring timely investigation and management. In an era of advanced molecular diagnostics in histopathology and biologic therapies, there is a notable gap in the literature regarding a general introduction to the overarching concepts of glomerular disease. This article aims to serve as a guide for medical students and internists, offering an overview of the approach to glomerular disease, including differential diagnoses, the clinical features of nephritis and nephrotic syndrome, and common presentations that aid in diagnosis, such as foamy urine, hematuria, and proteinuria.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 6","pages":"374-382"},"PeriodicalIF":1.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12919384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mobile health and hypertension in the digital era: patient perspectives on mHealth adoption and self-management in Saudi Arabia aligned with the digital health objectives of vision 2030. 数字时代的移动医疗和高血压:沙特阿拉伯患者对移动医疗采用和自我管理的看法与《2030年愿景》数字卫生目标一致。
IF 0.9 4区 医学
Asian Biomedicine Pub Date : 2025-10-31 eCollection Date: 2025-10-01 DOI: 10.2478/abm-2025-0031
Sultan M Alshahrani
{"title":"Mobile health and hypertension in the digital era: patient perspectives on mHealth adoption and self-management in Saudi Arabia aligned with the digital health objectives of vision 2030.","authors":"Sultan M Alshahrani","doi":"10.2478/abm-2025-0031","DOIUrl":"https://doi.org/10.2478/abm-2025-0031","url":null,"abstract":"<p><strong>Background: </strong>Hypertension remains a prominent public health concern in Saudi Arabia, contributing to cardiovascular morbidity and mortality. With widespread smartphone use and the national push toward digital transformation under Saudi Vision 2030, mobile health (mHealth) applications are a promising option for increasing self-management among hypertension patients.</p><p><strong>Objective: </strong>This study aims to analyze the acceptance, preferences, and perceived barriers toward utilizing mHealth applications for hypertension self-management among patients in Saudi Arabia.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted from January to March 2025 utilizing an online, self-administered questionnaire disseminated across the 5 administrative regions of Saudi Arabia. The study investigated demographics, clinical factors, technology utilization, preferred app features, attitudes, and readiness to adopt mHealth solutions. Descriptive statistics and Pearson correlation analysis were employed.</p><p><strong>Results: </strong>Among the 1098 respondents, 55.3% were female, and the mean age was 45.0 ± 11.8 years. A majority (95.2%) owned cellphones, although only 22.1% had used a health-related app, and 11.8% had used one for hypertension. Most participants reported great interest in app features like medication reminders (78.4%) and blood pressure tracking (71.9%). Willingness to utilize mHealth was high (85.6%), and substantially linked with education level (<i>P</i> = 0.008) and number of drugs (<i>P</i> = 0.03).</p><p><strong>Conclusion: </strong>The study reveals considerable support for mHealth integration into hypertension care in Saudi Arabia. Tailoring app design to user demands and aligning deployment with Vision 2030's digital health agenda can boost chronic illness management and patient empowerment nationally.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 5","pages":"296-302"},"PeriodicalIF":0.9,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12649393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145628052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The shifting burden of gastrointestinal and liver diseases in Southeast Asia and effective control strategies. 东南亚胃肠和肝脏疾病负担的转移及有效控制策略
IF 1.4 4区 医学
Asian Biomedicine Pub Date : 2025-10-31 eCollection Date: 2025-10-01 DOI: 10.2478/abm-2025-0027
{"title":"The shifting burden of gastrointestinal and liver diseases in Southeast Asia and effective control strategies.","authors":"","doi":"10.2478/abm-2025-0027","DOIUrl":"10.2478/abm-2025-0027","url":null,"abstract":"","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"19 5","pages":"218-219"},"PeriodicalIF":1.4,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12649389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145628038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书